The prognosis of chromosome 17 (chr17) abnormalities in patients with primary myelodysplastic syndrome (MDS) remains unclear. The revised International Prognostic Scoring System (IPSS-R) includes these abnormalities within the intermediate cytogenetic risk group.
INTRODUCTION

MATERIAL AND METHODS
Data Collection
The Spanish Registry of MDS is a database of the Spanish cooperative group on MDS. This database includes retrospective and prospective clinical and biological data from patients diagnosed of MDS at the participating institutions.
Patients and diagnostic criteria
A study group of 88 patients with primary MDS and an abnormality of chr17 along with a control group of 1,346 patients with primary MDS and an abnormal karyotype but without abnormalities of chr17 included in the database of the Spanish Registry of MDS constitute the population of the present report. The
diagnosis of MDS was made according to WHO 2001 criteria (ref. 2). The
following work is a retrospective study. We did not a specific study of the anomalies of the chr17 for lack of sufficient morphological data. However, several studies showed that some alterations of the chr17 are associated with the presence of hypercellularity, pseudo-Pelger-Huët, cells containing small vacuoles, prominent basophilia and eosinophilia, and marked increase of micromegakaryocytes (ref. [13] [14] [15] [16] .
In all patients included in this study, cytogenetic abnormalities have been In keeping with the guidelines of the Declaration of Helsinki, this retrospective non-interventional study was conducted with the approval of the internal review board from the participating institutions belonging to Spanish Registry of MDS.
Prognostic factors
The main prognostic factors evaluated for OS and AML transformation, recorded at the time of diagnosis, are summarized in Table 1 
Statistical analysis
Comparisons of proportions and ranges of variables between different groups were performed by Chi-square, Fisher, Student's t-test, Mann-Whitney U-test or One-Way ANOVA as appropriate.
The Kaplan-Meier product limit method was used to estimate the probability of OS and risk of AML transformation, OS was measured from hematological diagnosis to death or last follow-up. All deaths, whether related or not to MDS, were considered as the endpoint of the follow-up interval. AML transformation was measured from diagnosis to AML development. Patients dying from any cause before developing AML were considered as censored data in the date of death for the calculation of AML transformation curves. Statistical comparisons between different actuarial curves were based on log-rank tests.
Multivariate analysis using the Cox proportional hazards regression method for temporal events was used to identify the most significant independent prognostic variables for OS and AML transformation.
The selected p value for considering differences as statistically significant in all analyses was p<0.05. All analyses were performed using the statistical package PASW version 18.0 (IBM Corporation, Armonk, NY. USA).
RESULTS
Characteristics of the patients with abnormality of chr17
The main characteristics of the patients at the time of diagnosis are summarized in (n=14), abnormalities chr3 (n=13) and abnormalities chr1 (n=10).
There was a strong correlation between the number of chromosomal abnormalities found in addition to abnormalities of chr17 and particular characteristics of the MDS patients ( The monosomy 17 also had a worse prognosis than a complex karyotype without monosomy 17 with a median OS of 6 and 9.7 months, respectively (p=0.001).
In the multivariate analysis we analyzed the prognostic impact concerning OS and AML transformation of karyotype complexity, monosomy of chr17 and isochromosome 17 as independent variables using the Cox regression model for survival data. The results showed that monosomy 17 and complex karyotype were independent prognostic factors for OS with a hazard ratio of 1,98 (IC95%:
1,10-3,59; p=0,023) and 4,52 (IC95%: 2,20-9,34; p<0,001) respectively. For AML transformation, only complex karyotype was found as an independent prognostic factor with a hazard ratio of 4,59 (IC95%: 1,58-10,43; p=0,004).
Comparison of OS and transformation to AML between patients with chr17 abnormality and patients with other chromosomal abnormalities not involving chr17
We compared data of OS and AML transformation of 88 patients with chr17
abnormalities with data of 1,346 patients with other chromosomal abnormalities not involving chr17 from the Spanish registry of MDS.
In Figure 1 we observed that patients with abnormalities of chr17 have a worse prognosis than patients with an abnormal karyotype without chr17 abnormalities for median OS (8.7 vs 30.0 mo respectively (p <0.001)) and AML transformation (31% vs 22% respectively).
We compared the prognosis of the two groups of patients in each of the IPSS risk groups and IPSS cytogenetic risk groups (Table 4 ). In the IPSS Intermediate-2 risk group, patients with chr17 abnormality have a worse prognosis (median OS of 6.6 vs 14.0 mo in those without abnormality of chr17, p=0.005). In the IPSS cytogenetic risk groups of 1 point, the median OS of patients without abnormalities chr17 is of 29.1 months versus 11.9 months in patients with chr17 involved (p <0.001).
In table 5 we summarize the results restricted to the group of patients with poor prognosis according to IPSS. The patients with monosomy of chr17 had a worse prognosis and higher probability to progression to AML than patients with isolated monosomy of chr7 (median OS of 4.7 vs 19.0 mo, p<0.001; and median time to AML transformation (MTT) of 9.8 vs 36.0 mo, p=0.001, respectively). Also, monosomy of chr17 was associated with a worse survival than patients with complex karyotype without chr17 abnormalities (median OS of 4.7 vs 8.0 mo, p=0.015).
In addition ( In our study, patients with abnormality of chr17 typically presented poor prognostic features (Table 1) .
We found that patients with abnormalities of chr17 had a worse prognosis for OS and AML transformation than patients with abnormal karyotype but without abnormalities of chr17. These results were found within the homogeneous intermediate-2 IPSS-risk group and 1 point IPSS cytogenetic group as well.
When we analyzed the patients with complex karyotype, we found that if chr17 is involved, the prognosis is worsened.
Karyotype complexity is a well-known poor prognostic factor in MDS (ref. 4, 9, 11, 26-28). However, in MDS patients with anomaly of chr17 the prognostic value of the number of chromosomal abnormalities in addition to abnormality chr17 (complexity of the karyotype) has not been studied to date. We found two different prognostic groups of patients in function of number of chromosomal abnormalities: 1) patients with isolated abnormality of chr17 or with one associated abnormality and 2) patients with two or more associated abnormalities (p<0.001 and p=0.004 respectively).
The most frequent additional abnormalities to abnormality of chromosome 17
were: del(5q), followed by del(7q), monosomy 7, trisomy 8 and del(18q)/-18, the incidences of which were within the ranges reported in the literature (ref. 16, [29] [30] [31] [32] [33] [34] ).
Concerning the type of abnormality of chr17 we showed that the i(17q) as an isolated alteration have a median OS of 29.8 months, slightly higher than the survival described in the new proposal for cytogenetic categorization of MDS This could be explained because patients with -17 or add(17p) present complex karyotype in the majority of cases (p<0.001 and p=0.008 respectively) and the i(17q) is usually as single abnormality or additional ones (p<0.001). However, at multivariate analysis we found that monosomy 17 is an independent prognostic factor. When i(17q), was included within a group of poor prognosis according IPSS, had a worse prognosis than patients with isolated monosomy 7 but no differences with complex karyotype without chr17 involved.
Regarding patients with monosomy of chr17, we found a worse OS and major Finally, we analyzed the characteristics and outcome of 72 patients fulfilling the "loss chr17p" definition. Comparing the OS and risk of evolution to AML of patients with the "loss chr17p" vs those "without loss chr17p" no significant differences were observed between both groups. Our work is based on the results of conventional cytogenetics (karyotype), it is a retrospective study and LOH17, TP53 loss or TP53 mutations could not be studied. These molecular studies would be very interesting to confirm with prospective specimens. Abbreviations: BM, bone marrow; FAB, French-American-British; IPSS, International Prognostic Scoring System; RA, refractory anemia; RAEB, RA with excess of blasts; RARS, RA with ringed sideroblasts; RCDM, refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblasts; WHO, World Health Organization; i(17q), isochromosome 17q; -17, monosomy chr17; add(17p), additional 17p; +17, trisomy cr17; t17, translocation chr17. *In 4 patients WHO classification was not possible due to insufficient data. Table 4 Results OS between patients with abnormality of chr17 vs without abnormality of chr17 for each IPSS risk-group. 
